Nab-paclitaxel Plus S-1 Versus Nab-paclitaxel Plus Gemcitabine in Patients with Advanced Pancreatic Cancer: a Multicenter, Randomized, Phase II Study

Overview

Journal Oncologist

Publisher Oxford University Press

Specialty Oncology

Date 2024 Jul 11

PMID 38990195

Authors

Min Jin

Hong-Li Liu

Jun Xue

Hong Ma

Jun-Li Liu

Zhen-Yu Lin

Jing Wang

Le-Qun Bao

Zhi-Guo Luo

Xiong-Jie Yu

Shuang Li

Jian-Li Hu

Tao Zhang

Affiliations

Soon will be listed here.

Abstract

Background: Encouraging antitumor activity of nab-paclitaxel plus S-1 (AS) has been shown in several small-scale studies. This study compared the efficacy and safety of AS versus standard-of-care nab-paclitaxel plus gemcitabine (AG) as a first-line treatment for advanced pancreatic cancer (PC).

Methods: In this multicenter, randomized, phase II trial, eligible patients with unresectable, locally advanced, or metastatic PC were recruited and randomly assigned (1:1) to receive AS (nab-paclitaxel 125 mg/m2 on days 1 and 8; S-1 twice daily on days 1 through 14) or AG (nab-paclitaxel 125 mg/m2 on days 1 and 8; gemcitabine 1000 mg/m2 on days 1 and 8) for 6 cycles. The primary endpoint was progression-free survival (PFS).

Results: Between July 16, 2019, and September 9, 2022, 62 patients (AS, n = 32; AG, n = 30) were treated and evaluated. With a median follow-up of 8.36 months at preplanned interim analysis (data cutoff, March 24, 2023), the median PFS (8.48 vs 4.47 months; hazard ratio [HR], 0.402; P = .002) and overall survival (OS; 13.73 vs 9.59 months; HR, 0.226; P < .001) in the AS group were significantly longer compared to the AG group. More patients had objective response in the AS group than AG group (37.50% vs 6.67%; P = .005). The most common grade 3-4 adverse events were neutropenia and leucopenia in both groups, and gamma glutamyl transferase increase was observed only in the AG group.

Conclusion: The first-line AS regimen significantly extended both PFS and OS of Chinese patients with advanced PC when compared with the AG regimen, with a comparable safety profile. (ClinicalTrials.gov Identifier: NCT03636308).

References

Sun D, Cao M, Li H, He S, Chen W . Cancer burden and trends in China: A review and comparison with Japan and South Korea. Chin J Cancer Res. 2020; 32(2):129-139. PMC: 7219092. DOI: 10.21147/j.issn.1000-9604.2020.02.01. View

Tas F, Karabulut S, Ciftci R, Sen F, Sakar B, Disci R . Serum levels of LDH, CEA, and CA19-9 have prognostic roles on survival in patients with metastatic pancreatic cancer receiving gemcitabine-based chemotherapy. Cancer Chemother Pharmacol. 2014; 73(6):1163-71. DOI: 10.1007/s00280-014-2450-8. View

Vogel A, Rommler-Zehrer J, Shiansong Li J, McGovern D, Romano A, Stahl M . Efficacy and safety profile of nab-paclitaxel plus gemcitabine in patients with metastatic pancreatic cancer treated to disease progression: a subanalysis from a phase 3 trial (MPACT). BMC Cancer. 2016; 16(1):817. PMC: 5073820. DOI: 10.1186/s12885-016-2798-8. View

Zong Y, Yuan J, Peng Z, Lu M, Wang X, Shen L . Nab-paclitaxel plus S-1 versus nab-paclitaxel plus gemcitabine as first-line chemotherapy in patients with advanced pancreatic ductal adenocarcinoma: a randomized study. J Cancer Res Clin Oncol. 2020; 147(5):1529-1536. DOI: 10.1007/s00432-020-03442-0. View

Ohtake S, Kawahara T, Kasahara R, Ito H, Osaka K, Hattori Y . Pretreatment Neutrophil-to-Lymphocyte Ratio Can Predict the Prognosis in Bladder Cancer Patients Who Receive Gemcitabine and Nedaplatin Therapy. Biomed Res Int. 2016; 2016:9846823. PMC: 5086366. DOI: 10.1155/2016/9846823. View

Song H, Han B, Park C, Kim J, Jeon J, Kim I . Phase II trial of gemcitabine and S-1 for patients with advanced pancreatic cancer. Cancer Chemother Pharmacol. 2013; 72(4):845-52. DOI: 10.1007/s00280-013-2265-z. View

Luo G, Jin K, Deng S, Cheng H, Fan Z, Gong Y . Roles of CA19-9 in pancreatic cancer: Biomarker, predictor and promoter. Biochim Biophys Acta Rev Cancer. 2020; 1875(2):188409. DOI: 10.1016/j.bbcan.2020.188409. View

Zhang W, Du C, Sun Y, Yang L, Cui C, Jiang Z . Nab-paclitaxel plus S-1 as first-line followed by S-1 maintenance for advanced pancreatic adenocarcinoma: a single-arm phase II trial. Cancer Chemother Pharmacol. 2018; 82(4):655-660. PMC: 6132856. DOI: 10.1007/s00280-018-3650-4. View

Zhou Y, Wei Q, Fan J, Cheng S, Ding W, Hua Z . Prognostic role of the neutrophil-to-lymphocyte ratio in pancreatic cancer: A meta-analysis containing 8252 patients. Clin Chim Acta. 2018; 479:181-189. DOI: 10.1016/j.cca.2018.01.024. View

10.

Goonetilleke K, Siriwardena A . Systematic review of carbohydrate antigen (CA 19-9) as a biochemical marker in the diagnosis of pancreatic cancer. Eur J Surg Oncol. 2006; 33(3):266-70. DOI: 10.1016/j.ejso.2006.10.004. View

11.

Conroy T, Pfeiffer P, Vilgrain V, Lamarca A, Seufferlein T, OReilly E . Pancreatic cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2023; 34(11):987-1002. DOI: 10.1016/j.annonc.2023.08.009. View

12.

Cui J, Zhang X, Qu S, Wang L . Cost-effectiveness analysis of nab-paclitaxel plus gemcitabine versus folfirinox in the treatment of metastatic pancreatic cancer in china. Expert Rev Pharmacoecon Outcomes Res. 2020; 21(4):691-697. DOI: 10.1080/14737167.2020.1812386. View

13.

Chuah B, Goh B, Lee S, Soong R, Lau F, Mulay M . Comparison of the pharmacokinetics and pharmacodynamics of S-1 between Caucasian and East Asian patients. Cancer Sci. 2010; 102(2):478-83. DOI: 10.1111/j.1349-7006.2010.01793.x. View

14.

Zong Y, Peng Z, Wang X, Lu M, Shen L, Zhou J . Efficacy and Safety of Nab-Paclitaxel Plus S-1 versus Nab-Paclitaxel Plus Gemcitabine for First-Line Chemotherapy in Advanced Pancreatic Ductal Adenocarcinoma. Cancer Manag Res. 2020; 12:12657-12666. PMC: 7733895. DOI: 10.2147/CMAR.S263773. View

15.

Wolfe A, Siedow M, Nalin A, DiCostanzo D, Miller E, Diaz D . Increasing neutrophil-to-lymphocyte ratio following radiation is a poor prognostic factor and directly correlates with splenic radiation dose in pancreatic cancer. Radiother Oncol. 2021; 158:207-214. DOI: 10.1016/j.radonc.2021.02.035. View

16.

Shi Y, Zhang S, Han Q, Li J, Yan H, Lv Y . Nab-paclitaxel plus S-1 in advanced pancreatic adenocarcinoma (NPSPAC): a single arm, single center, phase II trial. Oncotarget. 2017; 8(54):92401-92410. PMC: 5696191. DOI: 10.18632/oncotarget.21359. View

17.

Cai J, Chen H, Lu M, Zhang Y, Lu B, You L . Advances in the epidemiology of pancreatic cancer: Trends, risk factors, screening, and prognosis. Cancer Lett. 2021; 520:1-11. DOI: 10.1016/j.canlet.2021.06.027. View

18.

Li J, Xu X, Han X, Fang Y, Shi C, Jin D . Nab-Paclitaxel Plus S-1 Shows Increased Antitumor Activity in Patient-Derived Pancreatic Cancer Xenograft Mouse Models. Pancreas. 2015; 45(3):425-33. DOI: 10.1097/MPA.0000000000000501. View

19.

Suenaga M, Yamada S, Fujii T, Tanaka C, Kanda M, Nakayama G . S-1 plus nab-paclitaxel is a promising regimen for pancreatic cancer in a preclinical model. J Surg Oncol. 2016; 113(4):413-9. DOI: 10.1002/jso.24147. View

20.

Uesaka K, Boku N, Fukutomi A, Okamura Y, Konishi M, Matsumoto I . Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01). Lancet. 2016; 388(10041):248-57. DOI: 10.1016/S0140-6736(16)30583-9. View